Table 3.

Change in the odds of having a Tanner stage >1 or having undergone menarche per IQR increase in ln-transformed urinary phthalate metabolite or BPA concentrations adjusted for age, BMI Z-score, and specific gravity.

In utero Urinary Metabolite Measurements (n=116)
	Menarche			Breast Development			Pubic Hair Development
	OR	95%CI	p-value	OR	95%CI	p-value	OR	95%CI	p-value
lnMEHP	0.91	0.31,2.73	0.87	0.86	0.34,2.19	0.75	5.30	1.13,24.95	0.03
lnMEHHP	1.62	0.54,4.81	0.39	0.66	0.29,1.54	0.34	2.66	0.80,8.82	0.11
lnMEOHP	1.55	0.52,4.63	0.43	0.73	0.31,1.74	0.48	2.31	0.73,7.31	0.16
lnMECPP	1.54	0.52,4.57	0.43	0.76	0.32,1.82	0.54	2.25	0.70,7.17	0.17
lnMBzP	0.89	0.33,2.38	0.82	1.88	0.82,4.30	0.13	1.60	0.50,5.06	0.43
lnMnBP	0.92	0.32,2.62	0.87	0.97	0.42,2.25	0.94	1.92	0.61,6.04	0.26
lnMiBP	0.42	0.12,1.50	0.18	0.70	0.25,1.95	0.49	1.52	0.33,6.89	0.59
lnMCPP	1.07	0.31,3.68	0.91	1.26	0.46,3.47	0.66	2.05	0.53,7.92	0.30
lnMEP	2.66	0.91,7.76	0.07	1.06	0.48,2.35	0.89	2.02	0.72,5.65	0.18
lnBPA	0.35	0.06,2.18	0.26	2.04	0.39,10.79	0.40	1.15	0.13,10.38	0.90

Peripubertal Measures Urinary Metabolites (n=129)
	Menarche			Breast Development			Pubic Hair Development
	OR	95%CI	p-value	OR	95%CI	p-value	OR	95%CI	p-value
lnMEHP	0.52	0.20,1.34	0.18	1.37	0.55,3.41	0.51	1.13	0.38,3.37	0.83
lnMEHHP	1.32	0.45,3.85	0.61	1.74	0.63,4.85	0.29	1.41	0.36,5.47	0.62
lnMEOHP	1.48	0.52,4.20	0.46	1.63	0.63,4.24	0.32	1.39	0.39,4.89	0.61
lnMECPP	1.22	0.44,3.33	0.70	1.45	0.57,3.69	0.43	1.22	0.35,4.23	0.76
lnMBzP	2.80	0.86,9.13	0.09	1.58	0.61,4.06	0.35	3.13	0.70,13.97	0.14
lnMnBP	1.21	0.47,3.16	0.69	2.41	0.95,6.06	0.06	2.64	0.85,8.23	0.09
lnMiBP	1.31	0.37,4.57	0.67	1.74	0.62,4.83	0.29	2.45	0.57,10.40	0.23
lnMCPP	0.95	0.37,2.42	0.91	1.48	0.69,3.18	0.31	1.63	0.62,4.31	0.32
lnMEP	2.58	0.90,7.39	0.08	1.55	0.60,3.97	0.36	1.91	0.59,6.21	0.28
lnBPA	0.44	0.14,1.36	0.16	0.99	0.33,2.96	0.99	0.68	0.20,2.33	0.54

OR, odds ratio; CI, confidence interval